Search: onr:"swepub:oai:gup.ub.gu.se/306791"
> (2021) >
Synthetic bacterial...
Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy
-
- Park, Kyong-Su (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Krefting Research Centre,Institute of Medicine
-
- Svennerholm, Kristina, 1981 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för anestesiologi och intensivvård,Institute of Clinical Sciences, Department of Anesthesiology and Intensive care
-
- Crescitelli, Rossella, 1985 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Krefting Research Centre,Institute of Medicine
-
show more...
-
- Lässer, Cecilia, 1981 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Krefting Research Centre,Institute of Medicine
-
- Gribonika, Inta (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi,Institute of Biomedicine, Department of Microbiology and Immunology
-
- Lötvall, Jan, 1956 (author)
- Gothenburg University,Göteborgs universitet,Krefting Research Centre,Institutionen för medicin,Institute of Medicine
-
show less...
-
(creator_code:org_t)
- 2021-07-03
- 2021
- English.
-
In: Journal of Extracellular Vesicles. - : Wiley. - 2001-3078. ; 10:9
- Related links:
-
https://onlinelibrar...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Bacterial outer membrane vesicles (OMV) have gained attention as a promising new cancer vaccine platform for efficiently provoking immune responses. However, OMV induce severe toxicity by activating the innate immune system. In this study, we applied a simple isolation approach to produce artificial OMV that we have named Synthetic Bacterial Vesicles (SyBV) that do not induce a severe toxic response. We also explored the potential of SyBV as an immunotherapy combined with tumour extracellular vesicles to induce anti-tumour immunity. Bacterial SyBV were produced with high yield by a protocol including lysozyme and high pH treatment, resulting in pure vesicles with very few cytosolic components and no RNA or DNA. These SyBV did not cause systemic pro-inflammatory cytokine responses in mice compared to naturally released OMV. However, SyBV and OMV were similarly effective in activation of mouse bone marrow-derived dendritic cells. Co-immunization with SyBV and melanoma extracellular vesicles elicited tumour regression in melanoma-bearing mice through Th-1 type T cell immunity and balanced antibody production. Also, the immunotherapeutic effect of SyBV was synergistically enhanced by anti-PD-1 inhibitor. Moreover, SyBV displayed significantly greater adjuvant activity than other classical adjuvants. Taken together, these results demonstrate a safe and efficient strategy for eliciting specific anti-tumour responses using immunotherapeutic bacterial SyBV.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- cancer immunotherapy
- synthetic bacterial vesicles
- tumour tissue
- extracellular vesicles
- outer-membrane vesicles
- dendritic cells
- escherichia-coli
- t-cells
- vaccine
- inflammation
- exosomes
- innate
- biogenesis
- expression
- Cell Biology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database